Bhuwan Swine Flu. Ppt

8/8/2019 Bhuwan Swine Flu. Ppt

http://slidepdf.com/reader/full/bhuwan-swine-flu-ppt 1/42

























































VACC INE



Target Groupy Adu lts d c il d r r si t s f

l -t r lt c d iti ,i cl ud i :

r ic l isease r ic eart isease r ic i ey isease r ic liver isease r ic e r l ical iseases ia etes ellit sImmuno supp ression



y Pregnant women at any stage of pregnancy.

y People who live in the same house as someone whose immune system is compromised by disease or treatment

y The vaccine is also being offered to health andsocial care staff who may be in close contact with people in the above groups.

**People who aren t in the priority groupslisted may be offered the vaccine at a later stage.



The U.S. Federal government has purchasedH1N1 vaccines from 5 pharmaceuticalcompanies:

y Novartis (Switzerland)y GlaxoSmithKline (United Kingdom)y Sanofi Pasteur (France) - PANENZA y

CSL (Australia)y MedImmune (U S A) Nasal spray V accine



y Novartis:

y Influenza A (H1N1) (killed) virus antigensy Mercury

(single dose syringe less than 1 mcg, multi-dose vial25 mcg per dose)

y Egg proteiny Beta-propiolactone (considered to be a carcinogen)y Nonylphenol ethoxylate (surfactant closely related to

nonoxynol-9 spermicide)



y Sanofi-Pasteur:

y Influenza A (H1N1) (killed) virus antigensy Thimerosal (approx. 49% mercury by weight)

(in the multi-dose vial only 25 mcg per dose,none in the single syringe)

y Formaldehydey Gelatiny Egg proteiny Polyethylene glycol p-isooctylphenyl ether

(detergent)y Sucrose (table sugar)



y PANENZA -is the pandemic Influenza vaccine used in

India, procured from M/s Sanofi Pasteur, France. Its Active Ingredients are :-

y

Split Influenza virus (propagated in eggs ),inactivated, containing antigen equivalent to: A/California/7/2009 (H1N1)v-like strain (NYMC X-179A) ..............15 micrograms per 0.5 ml dose .

y thiomersal (45 micrograms per 0.5 ml dose)y Sodium chloride, Potassium chloridey Disodium phosphate dihydrate, Potassium dihydrogen

phosphatey Water



y PANENZA is a suspension for injection in a multi-dose vial(10 doses of 0.5ml) - Pack of 10 vials. The suspension is a

colourless liquid, clear to opalescent.

y V accine administration : One dose (0.5 ml) intramuscular.

y Storage :Store in a refrigerator (2 0C 80C). D o not freeze .Keep the vial in the carton in order to protect from light. After first opening, use PANENZA within 7 days if stored ina refrigerator (2 0C 80C).



Possible Adverse Eventsy Common (affects 1 to 10 users in 100)

Headache, muscular pain.Pain at the injection site.

y Uncommon (affects 1 to 10 users in 1,000 )Feeling generally unwell, shivering, fever. At the injection site: redness, swelling.



y Rare (affects 1 to 10 users in 10,000)Skin Reactions - pruritus, urticaria, rash.NeuralgiaParaesthesia

Convulsions associated with feverNeurological disorders - stiff neck, confusion, numbness,pain and weakness of the limbs, loss of balance, loss of reflexes, paralysis of part or all the body (encephalomyelitis, neuritis, Guillain- Barre S yndrome) .Transient thrombocytopenia, Transient Lymphadenopathy. Allergic reactions ranging from simple to complex formslike Angioedema, Shock, V asculitis.



Indian Prospective A. India's first Self manufactured swine flu vaccine

V axiflu-S, has been manufactured by pharmaceutical major Cadila Healthcare on June 4,

2010 and is an egg-based, single dosed vaccine.y Its side effects, are minor which include fever, aches,

mild soreness. However, one in a million could beexposed to the risk of the Guillain Barre S yndrome - a

rare neurological disorder.y For now, the vaccine is meant only for those above the

age of 18. Trials for use by children will start now.



B. Pune sSerum Institute of India ( SII) launched aready-to-sniff intra-nasal vaccine, Nasovac ,on 15th July, 2010.

y It is a nasal spray in powder form, which has to be

reconstituted by adding water.y A single dose of 0.5ml of the vaccine is delivereddirectly to the nasal cavity through a device fitted atthe top of the syringe.

y

The body develops antibodies to protect against thedeadly virus for a period of over a year or even more.y According to experts, It has the efficiency to fight H1N1

infection even if small changes occur in the virus.



y The vaccine has been approved by the Drug Controllerof India (DCG I) and can be safely administered to any individual above three years .

y However, SII is not recommending the vaccine forpregnant women and lactating mothers.



Thank you

Documents

Bhuwan Swine Flu. Ppt